Effects of Exogenous Ketosis on Proteinuria and Renal Function
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorGødstrup Hospital
About this trial
A randomized, placebo-controlled, double-blinded crossover study will be conducted. Fourteen patients with polycystic kidney disease (PKD) and 29 patients with proteinuric kidney disease will receive ketone bodies (Ketone-IQ) and placebo in a randomized order. Each treatment period is four weeks. There will be a wash-out period of two weeks in between treatment periods. Effect variables will be measured in the last day of each treatment period.
Eligibility criteria
Qualifiers
ACR > 200 mg/g <3000 mg/g
eGFR >30 ml/min/1,73m2
Treatment with Renin-Angiotension System (RAS) blockers and SGLT-2 inhibitors for a minimum of 4 weeks prior to inclusion
Safe contraception if women in childbearing age
Disqualifiers
Diabetes Mellitus type 1
Heart Failure
Liver Disease
Kidney transplant
Trial design
Treatments tested in this trial
- Ketone Diol, R-1,3-butanediol (Ketone-IQ)
- Placebo drink
Treatment groups
43 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov